Skip to main content
Blood Advances logoLink to Blood Advances
. 2022 Nov 17;6(22):5885. doi: 10.1182/bloodadvances.2021005392

Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6):1695-1705.

PMCID: PMC9682109  PMID: 36378494

Page 1695: The data sharing statement in the footnotes, “Data requests may be submitted to Celgene, a Bristol-Myers Squibb company, at https://vivli.org/ourmember/celgene/ and must include a description of the research proposal,” should read “Bristol Myers Squibb policy on data sharing may be found at https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html.”

Page 1699, Table 2: Under “CRS only (n = 47)∗” and “NE only (n = 14)∗,” the column heading “Grade ≥3” should read “Grade 3.”

Page 1700, Table 3: In the left column, under “CRS only” and “NE only,” “≥3” should read “3.”

Page 1701, Table 4: Under “CRS only (n = 47)∗” and “NE only (n = 14)∗,” the column heading “Grade ≥3” should read “Grade 3.”

Page 1702, Table 5: Under “CRS only (n = 47)∗” and “NE only (n = 14)∗,” the column heading “Grade ≥3” should read “Grade 3.” In the second row of the left column, "otal" should read "total."

Page 1703, Figure 2: The label for the fourth bar from the right, “CRS & NE Grade ≥3 (n = 5),” should read, “CRS or NE Grade ≥3 (n = 5).”


Articles from Blood Advances are provided here courtesy of The American Society of Hematology

RESOURCES